Janus Henderson Group PLC Protagonist Therapeutics, Inc Transaction History
Janus Henderson Group PLC
- $194 Billion
- Q2 2025
A detailed history of Janus Henderson Group PLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 446,828 shares of PTGX stock, worth $34.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
446,828
Previous 21,454
1982.73%
Holding current value
$34.7 Million
Previous $1.04 Million
2281.49%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PTGX
# of Institutions
296Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$479 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$447 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$447 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$339 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$252 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.81B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...